A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Angiogenesis is the formation of new blood vessels and occurs physiologically during embryonal growth, wound healing and during the menstrual cycle. It is essential for the proliferation and metastases of most malignant neoplasms. Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Angiogenic cytokines such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor are expressed by myeloma cells and appear to play a role in the increased angiogenesis seen in myeloma. In addition, VEGF may serve as a paracrine growth factor for myeloma cells. Based on the increased angiogenesis observed in myeloma, thalidomide has been studied as antiangiogenic therapy. Although its mechanism of action in myeloma is still unclean thalidomide appears to be active in 25-30% of patients with refractory myeloma. Major toxicities include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. Studies are ongoing to determine its role as initial treatment for myeloma. This paper reviews the available data on angiogenesis in myeloma, and summarizes the role of thalidomide therapy in this disease. The pharmacology and toxicity of thalidomide are also discussed. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
Pages (from-to)351-362
Number of pages12
JournalCancer Treatment Reviews
Volume26
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Thalidomide
Multiple Myeloma
Vascular Endothelial Growth Factor A
Peripheral Nervous System Diseases
Fibroblast Growth Factor 2
Constipation
Therapeutics
Menstrual Cycle
Exanthema
Wound Healing
Fatigue
Blood Vessels
Intercellular Signaling Peptides and Proteins
Pharmacology
Cytokines
Neoplasm Metastasis
Growth
Neoplasms

Keywords

  • Angiogenesis
  • Antiangiogenic therapy
  • bFGF
  • Multiple myeloma
  • Thalidomide
  • Treatment
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{af00eaea397b4ff981dde00152dde08c,
title = "A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma",
abstract = "Angiogenesis is the formation of new blood vessels and occurs physiologically during embryonal growth, wound healing and during the menstrual cycle. It is essential for the proliferation and metastases of most malignant neoplasms. Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Angiogenic cytokines such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor are expressed by myeloma cells and appear to play a role in the increased angiogenesis seen in myeloma. In addition, VEGF may serve as a paracrine growth factor for myeloma cells. Based on the increased angiogenesis observed in myeloma, thalidomide has been studied as antiangiogenic therapy. Although its mechanism of action in myeloma is still unclean thalidomide appears to be active in 25-30{\%} of patients with refractory myeloma. Major toxicities include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. Studies are ongoing to determine its role as initial treatment for myeloma. This paper reviews the available data on angiogenesis in myeloma, and summarizes the role of thalidomide therapy in this disease. The pharmacology and toxicity of thalidomide are also discussed. (C) 2000 Harcourt Publishers Ltd.",
keywords = "Angiogenesis, Antiangiogenic therapy, bFGF, Multiple myeloma, Thalidomide, Treatment, VEGF",
author = "Rajkumar, {S Vincent} and Witzig, {Thomas Elmer}",
year = "2000",
doi = "10.1053/ctrv.2000.0188",
language = "English (US)",
volume = "26",
pages = "351--362",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma

AU - Rajkumar, S Vincent

AU - Witzig, Thomas Elmer

PY - 2000

Y1 - 2000

N2 - Angiogenesis is the formation of new blood vessels and occurs physiologically during embryonal growth, wound healing and during the menstrual cycle. It is essential for the proliferation and metastases of most malignant neoplasms. Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Angiogenic cytokines such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor are expressed by myeloma cells and appear to play a role in the increased angiogenesis seen in myeloma. In addition, VEGF may serve as a paracrine growth factor for myeloma cells. Based on the increased angiogenesis observed in myeloma, thalidomide has been studied as antiangiogenic therapy. Although its mechanism of action in myeloma is still unclean thalidomide appears to be active in 25-30% of patients with refractory myeloma. Major toxicities include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. Studies are ongoing to determine its role as initial treatment for myeloma. This paper reviews the available data on angiogenesis in myeloma, and summarizes the role of thalidomide therapy in this disease. The pharmacology and toxicity of thalidomide are also discussed. (C) 2000 Harcourt Publishers Ltd.

AB - Angiogenesis is the formation of new blood vessels and occurs physiologically during embryonal growth, wound healing and during the menstrual cycle. It is essential for the proliferation and metastases of most malignant neoplasms. Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Angiogenic cytokines such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor are expressed by myeloma cells and appear to play a role in the increased angiogenesis seen in myeloma. In addition, VEGF may serve as a paracrine growth factor for myeloma cells. Based on the increased angiogenesis observed in myeloma, thalidomide has been studied as antiangiogenic therapy. Although its mechanism of action in myeloma is still unclean thalidomide appears to be active in 25-30% of patients with refractory myeloma. Major toxicities include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. Studies are ongoing to determine its role as initial treatment for myeloma. This paper reviews the available data on angiogenesis in myeloma, and summarizes the role of thalidomide therapy in this disease. The pharmacology and toxicity of thalidomide are also discussed. (C) 2000 Harcourt Publishers Ltd.

KW - Angiogenesis

KW - Antiangiogenic therapy

KW - bFGF

KW - Multiple myeloma

KW - Thalidomide

KW - Treatment

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0033785490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033785490&partnerID=8YFLogxK

U2 - 10.1053/ctrv.2000.0188

DO - 10.1053/ctrv.2000.0188

M3 - Article

C2 - 11006136

AN - SCOPUS:0033785490

VL - 26

SP - 351

EP - 362

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 5

ER -